|By PR Newswire||
|August 27, 2013 05:15 PM EDT||
NEW YORK, Aug. 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight
Diabetes is one of the few disease areas that has retained its market value despite the entry of generics, the rise in drug prices and prevalence of the disease has allowed drug sales to soar to a worldwide value of $34.1 billion in 2012. While barriers to entry remain high with added scrutiny over cardiovascular and other safety risks, evident by Tresiba's (insulin degludec; Novo Nordisk) recent US failure, the exponential market growth makes diabetes one of the most attractive opportunities in Pharma.
Competition in the major drug segments are intense with Sanofi's basal insulin Lantus (insulin glargine), Novo's prandial insulin NovoRapid/NovoLog (insulin aspart), Merck's DPP-IV Januvia (sitagliptin), and Novo's GLP-1 Victoza (liraglutide) leading the way in their respective classes with best in class efficacy and safety. In addition to these clinical advantages, more convenient administration devices and strong marketing has helped them stand out from the competition.
While Novo Nordisk, Sanofi and Merck look set to protect their franchises with exciting pipeline therapies, Key Opinion Leaders interviewed by FirstWord note that there are a number of unmet needs in diabetes treatment and management. Companies that can address these needs and differentiate their products from existing players will see significant traction in this lucrative indication. This is evident from the successful launches of the novel SGLT-2 inhibitors- Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) and Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca), in the US and EU. In addition, therapies showing significant incremental advances also have potential to usurp market share from the gold standard treatments.
'Therapy Trends: Diabetes' is compiled from exclusive, in-depth interviews with the world's leading Key Opinion Leaders in diabetes. It identifies and analyses the major factors, advances and trends currently influencing the diabetes treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future Diabetes management.
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the diabetes disease area, and their scientific standing and clinical experience. Our unique KOL scoring system identifies those thought leaders with the greatest insight into how diabetes clinical research will shape the future market.
Diabetes: Battle for ascendancy escalates in expanding market examines the most prominent insights gained from the field's key opinion leaders. The results of FirstWord's research and analysis will help you to:
- Comprehend the current trends driving and shaping the global diabetes market
- Understand the future landscape and how new drug classes will fit into the treatment algorithm
- Compare and contrast the clinical profile of the insulins, DPP-IV, GLP-1 and SGLT-2 classes and assess their competitive strengths and weaknesses
- Assess the commercial and clinical potential of the next generation pipeline drugs, biosimilars, and existing therapies.
- Appreciate KOL calls for novel therapies and understand the commercial threat and opportunity for current products.
- Develop positioning strategies based on KOL insight
- Identify critical areas of unmet clinical need and opportunities for better disease management
- Evaluate the performance of companies with the most robust new product pipelines
- Recognise the key factors KOLs predict will drive future treatment trends
Critical questions answered
Diabetes: Battle for ascendancy escalates in expanding market answers key questions including:
- How might new therapies impact on the current first-line treatments?
- What are the current unmet needs and major challenges in diabetes treatment?
- What are the most promising late-stage classes in development?
- Which therapies are KOLs eagerly awaiting?
- How will the new therapies be positioned against each other in each of the disease segments?
- In what ways could players improve on existing therapies and what impact could this have on prescribing?
- How will treatment of diabetes look in the future?
- How do KOLs think the pricing environment is shaping the uptake of new diabetes treatments?
- What clinical research trends do KOLs predict for future diabetes therapies?
Diabetes Panel of Key Opinion Leaders
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the Diabetes disease area, and their scientific standing and clinical experience. The Diabetes KOL panel assembled for this Therapy Trends research is drawn from North America and Europe:
- Associate Professor of Endocrinology, University of Michigan, Ann Arbor, MI.
- Assistant Professor, Division of General Internal Medicines, John Hopkins University, Baltimore, MD.
- Clinical Associate Professor of Medicine, Division of General Internal Medicines, University of Washington School of Medicine, Washington.
- Director of the Clinical Diabetes Center at the University Hospital Albert Einstein College of Medicine, a Division of Montefiori Medical Center, NY
- Associate Professor of Medicine, Endocrinology and Metabolism, Duke University, Durham, NC.
- Professor of Endocrinology and Metabolic Diseases, University of Nantes; Head of the Internal Medicine, Endocrinology and Diabetes Department
- Honorary Consultant, Diabetes, University Hospital Leicester, Leicesteshire, UK
- Director, Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Basel, Switzerland.
- Professor, Professor of Medicine, Diabetes, Eberhard Karls University, University Hospital of Tuebingen, Germany.
- Professor of Medical Physiology, Department of Biomedical Sciences; Director of the Research Cluster for Diabetes and Obesity; Vice Chairman, Faculty of Health Sciences, University of Copenhagen, Denmark.
- Head, Diabeteszentrum Bad Lauterberg, Harz, Germany.
- Professor John Wilding, MD, Head of the Department of Obesity and Endocrinology, University of Liverpool, UK.
Future Event Updates
Dynamic clinical sectors develop. New product approvals/launches, extended indications or unexpected late-stage research failures/withdrawals can have a major impact on the treatment options for clinicians and performance of companies. What does such an event mean for stakeholders?
FirstWord's Therapy Trends Future Event Updates keep you one step ahead. As soon as a significant event has been identified we contact our KOL panelists to get their perspective of the event and what it means. This data is incorporated into the report and re-issued so the event can be seen in its wider market context.
This valuable service is included in the purchase price of the report and is provided for 12 months. You will receive fresh analysis every time a major market event breaks and a fully updated report will be delivered by to you one our consultants within days of each event's occurrence.
Whatever the event, Therapy Trends has the contacts, resources and knowledge to keep you up to date with what the latest market movements mean.
This report provides a qualitative overview of the current and future diabetes market. Information was gathered from telephone interviews held with twelve key opinion leaders (KOLs), from across the major diabetes markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also influence the dynamics of Pharma markets in other countries.
In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.
Subjects covered in the interviews included future diagnostic and therapeutic strategies for diabetes, the future of diabetes drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing diabetes drug classes, the cost of newer drugs and other concerns in the therapy area.
Current diabetes marketplace
Complications of diabetes
Current treatment landscape
Reimbursement of key diabetes brands
Current marketed therapies
Dipeptidyl Peptidase-IV (DPP-IV) inhibitors
Glucagon-like peptide-1 (GLP-1) agonists/analogues
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
Other non-insulin anti-diabetics
Pipeline basal insulins
Pipeline prandial insulins
Pipeline dipeptidyl peptidase-IV (DPP-IV) inhibitors
Pipeline glucagon-like peptide-1 (GLP-1) agonists/analogues
Pipeline sodium-glucose co-transporter 2 (SGLT-2) inhibitors
Other pipeline non-insulin anti-diabetics
Unmet needs in type 1 diabetes
Unmet needs in type 2 diabetes
Current treatment algorithm- Type2 diabetes
Future treatment algorithm
Future developments in Diabetes
To order this report:
Pathology Industry: Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
DevOps and microservices are permeating software engineering teams broadly, whether these teams are in pure software shops but happen to run a business, such Uber and Airbnb, or in companies that rely heavily on software to run more traditional business, such as financial firms or high-end manufacturers. Microservices and DevOps have created software development and therefore business speed and agility benefits, but they have also created problems; specifically, they have created software securi...
Feb. 22, 2017 11:00 AM EST Reads: 3,237
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Feb. 22, 2017 10:45 AM EST Reads: 341
Almost two-thirds of companies either have or soon will have IoT as the backbone of their business. Though, IoT is far more complex than most firms expected with a majority of IoT projects having failed. How can you not get trapped in the pitfalls? In his session at @ThingsExpo, Tony Shan, Chief IoTologist at Wipro, will introduce a holistic method of IoTification, which is the process of IoTifying the existing technology portfolios and business models to adopt and leverage IoT. He will delve in...
Feb. 22, 2017 10:00 AM EST Reads: 1,499
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Feb. 22, 2017 09:45 AM EST Reads: 1,324
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Feb. 22, 2017 09:45 AM EST Reads: 797
In his session at @ThingsExpo, Steve Wilkes, CTO and founder of Striim, will delve into four enterprise-scale, business-critical case studies where streaming analytics serves as the key to enabling real-time data integration and right-time insights in hybrid cloud, IoT, and fog computing environments. As part of this discussion, he will also present a demo based on its partnership with Fujitsu, highlighting their technologies in a healthcare IoT use-case. The demo showcases the tracking of pati...
Feb. 22, 2017 09:29 AM EST Reads: 149
Tricky charts and visually deceptive graphs often make a case for the impact IT performance has on business. The debate isn't around the obvious; of course, IT performance metrics like website load time influence business metrics such as conversions and revenue. Rather, this presentation will explore various data analysis concepts to understand how, and how not to, assert such correlations. In his session at 20th Cloud Expo, Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Sys...
Feb. 22, 2017 09:15 AM EST Reads: 1,379
@DevOpsSummit has been named the ‘Top DevOps Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @DevOpsSummit ranked as the number one ‘DevOps Influencer' followed by @CloudExpo at third, and @MicroservicesE at 24th.
Feb. 22, 2017 08:45 AM EST Reads: 1,131
Stratoscale, the software company developing the next generation data center operating system, exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016.Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere, IT is empowered to take control of their data ce...
Feb. 22, 2017 08:30 AM EST Reads: 850
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Feb. 22, 2017 08:30 AM EST Reads: 833
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his Day 2 Keynote at @ThingsExpo, Henrik Kenani Dahlgren, Portfolio Marketing Manager at Ericsson, discussed how to plan to cooperate, partner, and form lasting all-star teams to change the...
Feb. 22, 2017 08:15 AM EST Reads: 4,655
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
Feb. 22, 2017 08:00 AM EST Reads: 671
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...
Feb. 22, 2017 07:00 AM EST Reads: 2,937
To manage complex web services with lots of calls to the cloud, many businesses have invested in Application Performance Management (APM) and Network Performance Management (NPM) tools. Together APM and NPM tools are essential aids in improving a business's infrastructure required to support an effective web experience... but they are missing a critical component - Internet visibility.
Feb. 22, 2017 06:45 AM EST Reads: 1,639
Microservices are a very exciting architectural approach that many organizations are looking to as a way to accelerate innovation. Microservices promise to allow teams to move away from monolithic "ball of mud" systems, but the reality is that, in the vast majority of organizations, different projects and technologies will continue to be developed at different speeds. How to handle the dependencies between these disparate systems with different iteration cycles? Consider the "canoncial problem" ...
Feb. 22, 2017 06:00 AM EST Reads: 5,265